诱导多能干细胞技术在药物研发领域中的前景

发布时间：2018-06-26 14:39

本文选题：iPS细胞 + 药物研发　；参考：《中国生物工程杂志》2017年11期

【摘要】：由于基础研究环境和临床环境之间存在的转化差异,使得药物在临床阶段取得成功仍然具有挑战性。诱导多能干(iPS)细胞的诞生为药物研发领域带来了新的希望,使研究者能在体外人性化各种药理学和毒理学模型。人iPS衍生细胞的可获得性,特别是可以定向分化成特定的功能性细胞、组织和器官,一方面为疾病机制研究与细胞治疗提供了全新的途径。另一方面,转化研究中的生物标记物提供了评估临床前基础研究环境和临床环境下毒理学及药理学影响的可衡量的指标,而iPS细胞给生物标记物的研究带来了全新的思路。从转化研究的角度概述了基于iPS细胞药物发现的现行策略,阐明了iPS细胞的潜力以及生物标志物在药物发现和发展整个过程中的作用,突出在该领域有待改进的地方,以期为进一步相关性研究提供一定参考,为新药研发提供新的思路与方法。
[Abstract]:Because of the difference between the basic research environment and the clinical environment, the success of the drug in clinical stage is still challenging. The birth of induced pluripotent (iPS) cells brings new hope in the field of drug research and development and enables researchers to humanize various pharmacological and toxicological models in vitro. The availability of human iPS derived cells, especially the ability to differentiate into specific functional cells, tissues and organs, on the one hand, provides a new way for the study of disease mechanism and cell therapy. On the other hand, the biomarkers in the transformation study provide a measurable index to evaluate the toxicological and pharmacological effects of the pre-clinical basic research environment and the clinical environment, while iPS cells bring a new idea to the study of biomarkers. The current strategy of drug discovery based on iPS cells was summarized from the perspective of transformation research. The potential of iPS cells and the role of biomarkers in the whole process of drug discovery and development were clarified. In order to provide some reference for further correlation research and new ideas and methods for new drug research and development.
【作者单位】：江西中医药大学现代中药制剂教育部重点实验室;江西中医药大学中药固体制剂制造技术国家工程研究中心;成都中医药大学;
【基金】：江西省科技专项(20123BBG70201) 江西省重大科技专项(2010AZD00303)资助项目
【分类号】：R91

【相似文献】